Bax Over-expression Coupled With Bcl-2 Suppression Under The Control of The Cancer-specific Thymidine Kinase Promoter

Authors

Brian H. Ladle, Brigham Young University
Dr. Kim L. O'Neill, Brigham Young University

Keywords

bax gene, Bcl-2, cancer, thymidine kinase promotor, gene therapy

College

Life Sciences

Department

Microbiology and Molecular Biology

Abstract

As researchers continue to discover the molecular origins of cancer, gene therapy targeting cellular processes gone awry shows great promise as the future in cancer treatment. Extensive research is being done to develop more effective techniques targeting different cellular events. One pathway receiving increased attention is apoptosis (the default mechanisms activated intracellularly by extensive damage, causing the cell to kill itself). Often cancer will develop when genetic mutations or other cellular events render the cells unable to die by apoptosis. My research investigates a novel gene therapy that will restore the cancer cell’s ability to die by apoptosis, while limiting its expression and harmful effects in normal tissue.

Recommended Citation

Ladle, Brian H. and O'Neill, Dr. Kim L. (2014) "Bax Over-expression Coupled With Bcl-2 Suppression Under The Control of The Cancer-specific Thymidine Kinase Promoter," Journal of Undergraduate Research: Vol. 2014: Iss. 1, Article 813.
Available at: https://scholarsarchive.byu.edu/jur/vol2014/iss1/813